placebo + tramadol

The combination of placebo and tramadol refers to a specific control intervention arm used in a Phase 4 clinical trial (NCT01155310) conducted by the University of Southern Denmark. This crossover study was designed to evaluate the effect of multiple doses of the antidepressant escitalopram on the pharmacokinetics and pharmacodynamics of a single dose of tramadol in healthy subjects. In this particular arm, subjects received a placebo (as a comparator for escitalopram) for nine days, followed by a single 150 mg dose of tramadol on the ninth day. Tramadol is a centrally acting analgesic that functions as a mu-opioid receptor agonist and a serotonin-norepinephrine reuptake inhibitor (SNRI). The inclusion of Major Depressive Disorder in the identifier likely refers to the primary indication of escitalopram, the drug being studied for potential interactions with tramadol.

Other names

placebo and tramadol